Boosted Protease Inhibitors

Ritonavir-boosted Darunavir (Prezista) Is Well Tolerated by Treatment-experienced Patients in POWER 1, 2 and 3 Trials - 8/29/06

48-Week Efficacy and Safety of Ritonavir-boosted Tipranavir in Children and Teenagers - 8/29/06

Impact of Boosted vs Unboosted Atazanavir-based Regimens on the Lipid Profiles of HIV Positive Patients - 8/29/06

Economic and Clinical Impact of Using Atazanavir + Ritonavir versus Lopinavir/Ritonavir- 8/25/06

Boosted Lopinavir/Ritonavir plus Saquinavir without Additional Anti-HIV Therapy - 8/25/06

Atazanavir/Ritonavir versus Efavirenz: Retrospective Review of a Large US Cohort  - 8/22/06

Treatment with Atazanavir with or without Ritonavir Results in Clinically Important Improvements in Health-related Quality of Life  - 8/22/06

Selection of Protease Inhibitor-Resistance Mutations During Failure of Lopinavir/ritonavir Monotherapy  - 8/22/06

The KLEAN Study: Fosamprenavir + Ritonavir versus Lopinavir/Ritonavir   - 8/18/06

Impact of Prior PI Usage on Week 48 Responses to Tipranavir Boosted with Ritonavir   - 8/18/06

Tipranavir/Ritonavir Is More Effective against Protease Inhibitor (PI)-resistant Strains than Other Ritonavir-boosted PIs   - 8/18/06

The Non-peptidic HIV Inhibitor Tipranavir Modulates Pneumocystis in vitro Growth   - 8/18/06

Does Optimal Timing of HAART Initiation Differ with Newer Treatment Regimens That Include Efavirenz or Ritonavir-boosted Protease Inhibitors?   - 8/18/06

Darunavir Provides Durable HIV Suppression in Treatment-experienced Patients: Week 48 analysis of POWER 1 and 2   - 8/15/06